News & Views | Published:

Cancer systems biology

Harnessing off-target effects

Nature Chemical Biology volume 13, pages 12041205 (2017) | Download Citation

The 'off-targets' of a drug are often poorly characterized yet could be harnessed in the treatment of complex diseases. A recent study used a small-molecule screening in non-small-cell lung cancer to repurpose an FDA-approved ALK/IGF1R inhibitor and uncover its mechanism of action.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , & Adv. Drug Deliv. Rev. 98, 19–34 (2016).

  2. 2.

    A. & Jr. Nat. Rev. Cancer 5, 65–72 (2005).

  3. 3.

    & Nat. Rev. Drug Discov. 6, 881–890 (2007).

  4. 4.

    Nat. Chem. Biol. 4, 682–690 (2008).

  5. 5.

    et al. Nat. Chem. Biol. 13, 1222–1231 (2017).

  6. 6.

    , , & Nat. Rev. Cancer 17, 502–508 (2017).

  7. 7.

    & Trends Genet. 9, 138–141 (1993).

  8. 8.

    et al. Clin. Pharmacol. Ther. 94, 646–650 (2013).

  9. 9.

    et al. Nat. Med. 20, 1027–1034 (2014).

  10. 10.

    et al. J. Thorac. Oncol. 11, 1550–1557 (2016).

Download references

Author information

Affiliations

  1. Gaye Saginc, Franziska Voellmy and Rune Linding are at Biotech Research and Innovation Center, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

    • Gaye Saginc
    • , Franziska Voellmy
    •  & Rune Linding
  2. Franziska Voellmy is also at the Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark.

    • Franziska Voellmy

Authors

  1. Search for Gaye Saginc in:

  2. Search for Franziska Voellmy in:

  3. Search for Rune Linding in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Rune Linding.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nchembio.2519

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing